(Q38222470)

31 August 2017

Novel pancreatic cancer vaccines could unleash the army within (English)

1 reference

31 August 2017

1 reference

Gregory M Springett

1

1 reference

31 August 2017

1 July 2014

1 reference

31 August 2017

1 reference

31 August 2017

21

1 reference

31 August 2017

3

1 reference

31 August 2017

242-246

1 reference

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

31 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

Oncology meets immunology: the cancer-immunity cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481402100311

10.1177/107327481402100311

21 January 2018

Identifiers

DOI

0 references

PubMed ID

24955709

1 reference

PubMed ID

24955709